Form 4: Sonoma Pharmaceuticals Director John McLaughlin Awarded Stock Options
SEC Form 4 Filing
Director John McLaughlin receives stock options for services performed on the Board of Directors of Sonoma Pharmaceuticals, Inc.
Summary
- John McLaughlin, a director of Sonoma Pharmaceuticals, Inc., was granted stock options on January 2, 2025.
- The options allow him to purchase 7,500 shares of common stock at an exercise price of $2.68 per share.
- The options vest in three equal installments on January 2, 2026, January 2, 2027, and January 2, 2028, or upon a change of control.
- Following the transaction, McLaughlin directly owns 10,044 shares.
- The options expire on January 2, 2035.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. It indicates continued investment in the company's leadership.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants to board members are a common practice across the pharmaceutical industry.
- Companies like Amgen and Pfizer also use stock options as part of their compensation packages for directors.
- The vesting schedule of one-third each year for three years is a typical vesting arrangement.
- The exercise price is usually set at or above the market price on the grant date.
Stakeholder Impact
- The stock option grant aligns the director's interests with shareholders, potentially leading to better corporate governance and decision-making.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction (grant of stock options) |
| 01/02/2026 | First vesting date for one-third of the options |
| 01/02/2027 | Second vesting date for one-third of the options |
| 01/02/2028 | Third vesting date for one-third of the options |
| 01/02/2035 | Expiration date of the stock options |
| 01/03/2025 | Date of signature on the Form 4 filing |
Keywords
stock options, director, SNOA, Sonoma Pharmaceuticals, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.